Growth signals, such as extracellular nutrients and growth factors, have substantial effects on genome integrity; however, the direct underlying link remains unclear. Here, we show that the mechanistic target of rapamycin (mTOR)-ribosomal S6 kinase (S6K) pathway, a central regulator of growth signalling, phosphorylates RNF168 at Ser60 to inhibit its E3 ligase activity, accelerate its proteolysis and impair its function in the DNA damage response, leading to accumulated unrepaired DNA and genome instability. Moreover, loss of the tumour suppressor liver kinase B1 (LKB1; also known as STK11) hyperactivates mTOR complex 1 (mTORC1)-S6K signalling and decreases RNF168 expression, resulting in defects in the DNA damage response. Expression of a phospho-deficient RNF168-S60A mutant rescues the DNA damage repair defects and suppresses tumorigenesis caused by Lkb1 loss. These results reveal an important function of mTORC1-S6K signalling in the DNA damage response and suggest a general mechanism that connects cell growth signalling to genome stability control.
A s organisms are often exposed to environmental and internal challenges that cause DNA damage, efficient and accurate DNA repair systems are crucial for maintaining genome integrity and organism subsistence 1, 2 . For instance, non-homologous end joining and homologous recombination are the two major mechanisms responsible for timely and efficient repair of DNA double-strand breaks (DSBs) 3 , the most harmful type of DNA damage that is pathologically linked to human diseases such as cancer 4, 5 . Briefly, when DSBs occur, the MRE11-RAD50-NBS1 (MRN) complex initiates signalling cascades by recruiting activated ATM kinase to the lesion sites, which rapidly phosphorylates histone H2A.X (γ H2A.X). Then, mediator of DNA damage checkpoint protein 1 (MDC1) is recruited to the damage sites via the interaction between its BRCT domain and phosphorylated γ H2A.X to act as a scaffold molecule for the E3 ligases RNF8 and RNF168 (refs [6] [7] [8] [9] ) to build and amplify histone ubiquitylation signals. Independent accumulation of p53-binding protein 1 (53BP1) and the RAP80-BRCA1 complex further recruits two different sets of functional factors to initiate the non-homologous end joining or homologous recombination repair process, respectively. As such, DSB repair is precisely controlled by delicate and complicated signalling cascades.
Mechanistic target of rapamycin (mTOR) belongs to the phosphatidylinositol-3-OH kinase-related kinases family and is an essential regulator of cell homeostasis, including protein translation, glucose and lipid metabolism, cell survival and autophagy 10 . Upon activation by extracellular growth signals, such as growth factors, amino acids and insulin, mTOR promotes the phosphorylation of hundreds of substrates directly or indirectly via activating downstream kinases, including ribosomal S6 kinase (S6K), AKT, protein kinase C (PKC) and SGK, by forming two distinct kinase complexes, mTOR complex 1 (mTORC1) and mTORC2, respectively 10 . Thus, mTOR is a central player that senses and responds to various extracellular growth signals. Emerging evidence has indicated that metabolic alterations have a role in genome stability control 11, 12 , which involves mTOR and its negative regulator, such as liver kinase B1 (LKB1; also known as STK11) [13] [14] [15] [16] [17] [18] [19] [20] . However, the underlying molecular link remains unclear.
In this study, we found that the mTORC1-S6K pathway regulates the DNA damage response (DDR) through phosphorylation of RNF168 at Ser60, which inhibits its E3 ligase activity to ubiquitinate histones. Furthermore, Ser60 phosphorylation increases RNF168
The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNF168 interaction with the E3 ubiquitin ligase TRIP12, leading to enhanced RNF168 degradation. Importantly, depletion of the tumour suppressor LKB1, which causes hyperactivation of mTORC1, dramatically decreases RNF168 abundance and subsequently impairs the DDR. Notably, expression of the phospho-deficient RNF168-S60A (SA) mutant rescued DDR defects caused by LKB1 depletion, and suppressed tumorigenesis in a mouse lung adenocarcinoma model. Thus, the mTORC1-S6K pathway may contribute to growth signalmediated genome instability via inhibition of RNF168 function.
Results
The mTORC1-S6K pathway inhibits the DDR. We observed that cells were deficient in repairing DSBs induced by etoposide or ionizing radiation (IR) in the presence of amino acids, as evidenced by the sustained levels of γ H2A.X and the extended lengths of tail moments ( Fig.1a and Supplementary Fig. 1a,b) . Given that amino acids have been shown to activate mTORC1 and its downstream substrate S6K 10, 21 , we reasoned that mTORC1-S6K signalling, a central metabolism regulatory pathway 22 , may modulate the DDR. To further examine this hypothesis, we challenged S6k1 and S6k2 double knockout (S6k -/-) mouse embryo fibroblast (MEF) cells with IR to induce DSBs, and determined the kinetics of cell recovery from DNA damage by monitoring γ H2A.X/53BP1 foci and tail moments of neutral comet assays. Interestingly, enhanced ability to repair damaged DNA, as evidenced by reduced numbers of γ H2A.X-positive cells and shortened tail moments, were observed in S6k -/cells compared with wild-type (WT) cells after 2 h post-IR treatment (Fig. 1b-d and Supplementary Fig. 1c ). Moreover, an increase in homologous recombination-mediated DSB repair was also observed in homology-directed repair of green fluorescent protein (DR-GFP) reporter cells 23 , as evidenced by increased numbers of GFP-positive cells after S6K1 depletion (Fig. 1e) , and more S6k -/cells survived after IR treatment when compared with WT cells (Fig. 1f ). These data indicate that S6K may negatively regulate DSB repair in cells.
In support for a critical role of S6K in suppressing ubiquitin signalling upon DNA damage, we observed significantly increased FK2 foci staining for ubiquitin signals in S6k -/cells after IR treatment compared with control cells (Fig. 1g,h and Supplementary  Fig. 1d ,e), and re-expression of S6K1 in S6k -/-MEF cells reduced FK2 foci staining after IR ( Supplementary Fig. 1f -h). To further examine whether the kinase activity of mTORC1 has a role in regulating ubiquitin signalling, we observed that rapamycin could rescue the significantly reduced ubiquitin foci upon IR challenge in Lkb1 -/-MEF cells 24 with hyperactivated mTORC1-S6K signalling ( Fig. 1i-k) . These data indicate that the kinase activity of mTORC1 is essential in regulating ubiquitin signalling during DSB repair. It has been reported that the type A histone polyubiquitylation at the damage sites is critical for subsequent DSB repair 8, 9, 25 ; thus, mTORC1-S6K signalling may modulate the histone polyubiquitylation step of the DDR to suppress DSB repair.
S6K phosphorylates RNF168 at Ser60. Given that the E3 ubiquitin ligase RNF168 (refs 8, 9 ) was identified and characterized as the key enzyme in generating histone polyubiquitylation at the DNA damage sites, we next examined whether mTORC1-S6K signalling may directly phosphorylate and regulate RNF168. To this end, using a proteomic approach, we identified Ser60 phosphorylation in the amino-terminal of RNF168 as the only phosphorylation site responding to amino acid treatment out of a total of 11 phosphorylation sites identified ( Fig. 2a and Supplementary Fig. 2a,b ). Using an antibody that specifically recognizes RNF168-Ser60 phosphorylation ( Supplementary Fig. 2c ), we found that co-expression with S6K1 or amino acid stimulation dramatically promoted the RNF168-Ser60 phosphorylation signal of both endogenous and ectopically expressed RNF168-WT, but not the RNF168-SA, whereas inhibition of mTORC1-S6K signalling by depletion of S6K1 or rapamycin treatment efficiently blocked this process ( Fig. 2b-g and Supplementary Fig. 2d ). Furthermore, we observed that bacterially purified RNF168-WT, but not RNF168-SA, was efficiently phosphorylated by purified S6K1, which provides support of a direct role for S6K in phosphorylating RNF168 at Ser60 ( Fig. 2h and Supplementary Fig. 2e ). More importantly, in vitro phosphorylation of RNF168 could be efficiently blocked by the S6K1 inhibitor PF4708671, but not by the mTOR inhibitor rapamycin (Fig. 2h ). Together, these data indicate that S6K, but not mTORC1, directly phosphorylates RNF168 at Ser60 in vitro.
Ser60 phosphorylation impairs RNF168 E3 ligase activity and results in DDR defects. As the Ser60 residue is adjacent to the RING motif of RNF168, which is critical for its E3 ligase activity 8, 9 , we next investigated whether Ser60 phosphorylation influences the function of RNF168 in histone ubiquitylation and the DDR. Strikingly, compared with RNF168-WT, the phospho-mimetic RNF168-S60E (SE) mutant failed to promote polyubiquitylation of both endogenous and transfected H2A, similar to the enzymatic-dead RNF168 (C19S) mutant 9 ( Fig. 3a and Supplementary Fig. 2f ). These data indicate that Ser60 phosphorylation may interfere with the E3 ligase activity of RNF168. Furthermore, we found that the functional deficiency of RNF168-SE in H2A ubiquitylation was largely caused by its reduced E3 ligase activity ( Fig. 3b and Supplementary Fig. 2g ,h), but not by deficiency in discharging the E2 ubiquitin complexes 9, 26 ( Supplementary Fig. 2i ). Overall, these data indicate that phosphorylation of RNF168 at the Ser60 residue inhibits its E3 ligase activity.
Next, we further examined whether RNF168-Ser60 phosphorylation impairs its major function in the DDR, such as facilitating the recruitment of 53BP1 to the damage sites 25 . To this end, we generated a Tet-inducible RNF168 knock-down HCT116 cell line ( Supplementary Fig. 3a ) and reconstituted the cells with short hairpin RNA (shRNA)-resistant RNF168 constructs encoding RNF168-WT, RNF168-SE and RNF168-SA. We observed less 53BP1 foci in RNF168-SE-expressing cells than in RNF168-WT-expressing or RNF168-SA-expressing cells ( Supplementary  Fig. 3b ,c), which suggests that S6K-mediated Ser60 phosphorylation inhibits RNF168 E3 ligase activity and subsequently impairs its role in the DDR. To more rigorously examine the functional impact of RNF168-Ser60 phosphorylation, we generated RNF168-SA and RNF168-SE knock-in (KI) mice using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) technique ( Supplementary Fig. 3d ), and isolated MEF cells to examine their DDR efficiency after IR treatment. Compared with WT and RNF168-SA KI MEF cells, significantly reduced numbers of 53BP1 foci and significantly sustained numbers of γ H2A.X foci were observed in RNF168-SE KI MEF cells ( Fig. 3c,d and Supplementary Fig. 3e ). The deficiency of DNA damage repair was also supported by the observation that the average tail moment of RNF168-SE KI MEF cells was significantly longer than that of RNF168-WT and RNF168-SA KI MEF cells in the comet assays post-IR ( Fig. 3e ). Furthermore, increased numbers of γ H2A.X-positive cells were observed in the lung tissue of RNF168-SE KI mice after IR treatment, whereas both class-switch recombination of primary B cells and the average intestinal villi length of RNF168-SE KI mice post-IR treatment were significantly lower than in RNF168-WT and RNF168-SA KI mice ( Fig. 3f-j and Supplementary Fig. 3f ,g). Cumulatively, these data support the finding of a substantially impaired and delayed DNA damage repair caused by S6K-mediated RNF168 phosphorylation at Ser60.
The mTORC1-S6K pathway destabilizes RNF168. Interestingly, although there were reduced levels of Rnf168 mRNAs in S6k -/--MEF cells, accumulated RNF168 protein was detected in S6k -/--MEF cells compared with WT MEF cells ( Fig. 4a,b) , which is probably . Ctrl, control. A plasmid encoding endonuclease I-Sce I was transfected to generate DSBs as indicated. f, Relative cell survival of WT and S6k -/-MEF cells exposed to the indicated doses of IR (n = 3 independent experiments). g,h, Representative images (g) and quantification (h) (n = 3 independent experiments) of conjugated ubiquitin (Ub (FK2)) foci-positive WT MEF cells and S6k -/cells 2 h after IR (4 Gy) treatment. Scale bars, 10 μ m. i-k, Representative images (i) and quantification of FK2 (j) positive WT and Lkb1 -/-MEF cells. As indicated, Lkb1 -/-MEF cells were pre-treated with or without rapamycin (50 nM) for 1 h before exposure to IR (4 Gy) treatment. Cells were fixed for immunofluorescence experiments 2 h post-IR (n = 3 independent experiments). Scale bars, 10 μ m. Effects of rapamycin treatment were validated with the indicated antibodies (k). Unpaired Student's t-test was used (NS, not significant, *0.01 < P < 0.05, **0.001 < P < 0.01 and ***P < 0.001), and data are shown as mean ± s.e.m. Statistics source data can be found in Supplementary Table 3 .
The immunoblots are representative of three independent experiments. Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
independent of cell cycle or proliferation status ( Supplementary  Fig. 3h -j). Moreover, the half-life of RNF168 was dramatically extended in S6k -/--MEF cells ( Fig. 4c ), suggesting that S6K may modulate RNF168 stability. Depletion of the mTORC1-S6K pathway components, such as mTOR, Raptor or S6K, consistently led to dramatically elevated RNF168 levels ( Fig. 4d-f ). Conversely, expression of S6K1 in S6k -/--MEF cells drastically decreased RNF168 levels and delayed the decrease of γ H2A.X levels post-etoposide treatment ( Fig. 4g and Supplementary Fig. 3k ). Moreover, MG132 treatment blocked S6K1 mediated-RNF168 decrease, and expressing an enzymatic-dead mutation (KR) of S6K1 did not affect RNF168 stability ( Fig. 4h ), suggesting that S6K modulates RNF168 stability in a S6K activity and 26 S proteasome-dependent manner. As RNF168 is phosphorylated by S6K at Ser60, we continued to investigate whether S6K governs RNF168 stability in a Ser60 phosphorylation-dependent manner. To this end, we observed that ectopic expression of S6K1 dramatically shortened the halflife of RNF168-WT, but not the phospho-deficient RNF168-SA mutant ( Fig. 4i ). Next, we examined whether physiological cues that modulate the mTORC1-S6K pathway regulate RNF168 levels. Interestingly, amino acid deprivation efficiently inhibited S6K, leading to increased RNF168 levels, which could be reversed by Supplementary Table 3 .
-
The immunoblots are representative of three independent experiments. Unprocessed original scans of blots are in Supplementary Fig. 8 . was added and cells were harvested at the indicated time points for immunoblot analysis. j, 293T cells were cultured in amino-acid-free (-AA) medium for the indicated period of time, then were harvested directly or at the indicated time points after re-addition of amino acids (+ AA) for immunoblot analysis. k,l, Representative images of RNF168 and pS6 signals in tissue microarrays containing 53 sets of clinical lung adenocarcinoma tissues and paired adjacent normal tissues as assessed by immunohistochemistry. Scale bars, 100 μ m. Both RNF168 and pS6 levels were classified as low and high based on the intensities of the immunohistochemistry staining, and the number of tissues classified in each category is depicted in the tabulation in panel l. Chi-squared test was used to support a significant inverse correlation (P = 0.000329, 95% CI: 0.369-0.765) between RNF168 and pS6 levels in clinical samples. The numbers of samples with high or low RNF168 and pS6 levels are indicated. Unpaired Student's t-test was used for panel b (***P < 0.001), and data are shown as mean ± s.e.m. Statistics source data can be found in Supplementary Table 3 . The immunoblots are representative of three independent experiments. Unprocessed original scans of blots are in Supplementary Fig. 8 .
re-addition of amino acids (Fig. 4j) . Similarly, serum re-feeding also quickly activated mTORC1-S6K signalling and decreased RNF168 expression, which was blocked by rapamycin treatment ( Supplementary Fig. 3l ). Together, these data demonstrate that mTORC1-S6K signalling regulates RNF168 protein turnover through phosphorylating RNF168 at Ser60. To determine whether there is a pathological correlation between mTORC1 activation and RNF168 expression, we examined the level of RNF168 and phospho-S6 ribosomal protein Ser240/S244 (pS6) 27 signals, an indicator of mTORC1-S6K pathway activity, in tissue microarrays, including clinical non-small-cell lung adenocarcinoma samples paired with adjacent normal tissues as controls. Interestingly, RNF168 expression was significantly inversely correlated with pS6 signals (P = 0.000329), which was frequently observed in tumour tissues (Fig. 4k,l ). In addition, we observed an inverse correlation between RNF168 levels and pS6 signals in 10 out of 11 lung cancer samples ( Supplementary Fig. 3m ). These results suggest that RNF168 expression may be negatively associated with the activated mTORC1 pathway in pathological conditions. Taken together, these data indicate that the activated mTORC1-S6K pathway destabilizes RNF168 in a Ser60 phosphorylationdependent manner.
Ser60 phosphorylation promotes TRIP12-mediated RNF168 degradation. As TRIP12 has been reported as the major E3 ligase governing RNF168 stability 28 , we further investigated whether mTORC1-S6K signalling modulates TRIP12-mediated RNF168 destruction. Notably, short interfering RNA (siRNA)-mediated depletion of TRIP12 completely blocked the decrease in the levels and polyubiquitylation of RNF168 triggered by ectopically expressed S6K1 (Fig. 5a,b) , supporting an essential role of TRIP12 in RNF168 ubiquitylation and destruction. U2OS cells that stably express Flag-RNF168 were used to detect the binding of endogenous TRIP12 to Flag-RNF168 after physiological activation of the mTORC1-S6K pathway with insulin; the interaction of TRIP12 to RNF168 was dramatically increased by insulin treatment but blocked by rapamycin ( Fig. 5c ). Furthermore, ectopic expression of S6K1 or amino acid treatment enhanced TRIP12 binding to RNF168-WT, but not to the RNF168-SA mutant (Fig. 5d,e ). Moreover, depletion of TRIP12 led to the accumulation of RNF68-WT and RNF168-SE, but not to RNF168-SA abundance, which did not bind to TRIP12 (Fig. 5f,g ), suggesting that RNF168 with Ser60 phosphorylation may be a more sensitive substrate for TRIP12. Interestingly, TRIP12 seems to bind to RNF168 via its N-terminal region (1-749 amino acids) ( Fig. 5h,i) .
Overall, these results suggest that mTORC1-S6K signalling governs RNF168 stability in a RNF168-Ser60 phosphorylation and TRIP12dependent manner.
LKB1 governs RNF168 abundance via the mTORC1-S6K pathway. By phosphorylating 5′ -AMP-activated protein kinase (AMPK) and many other substrates, LKB1 is considered to be a major tumour suppressor and metabolism regulator that inhibits the mTORC1-S6K pathway 29 . As LKB1 mutation is frequently observed in various cancers and results in aberrant mTORC1 activation 24, 29 , we next explored whether LKB1 depletion has any effect on RNF168 expression, activity and the DDR. We observed dramatically reduced RNF168 levels in Lkb1 -/cells compared with WT MEF cells, which may be due to a shortened half-life ( Supplementary  Fig. 4a,b ). In addition, RNF168 levels were significantly reduced upon depletion of LKB1 ( Fig. 6a and Supplementary Fig. 4c ).
Notably, depletion of LKB1 led to increased RNF168-Ser60 phosphorylation levels through activating the mTORC1-S6K pathway ( Fig. 6b and Supplementary Fig. 4d ). Thus, we reasoned that activation of the mTORC1-S6K pathway is possibly the major cause of reduced RNF168 expression upon LKB1 loss. In keeping with this notion, inhibition of mTORC1-S6K signalling by depleting S6K1
or Raptor, restored RNF168 expression in LKB1-depleted U2OS cells (Fig. 6c ). Thus, LKB1 largely modulates RNF168 expression through the mTORC1-S6K pathway. LKB1 has been implicated to play an important part in the DDR 30 , and loss of LKB1 causes decreased DNA repair efficiency 13 . As RNF168 levels are tightly associated with LKB1 status ( Fig. 6a and Supplementary Fig. 4a,b) , we next examined whether LKB1 loss causes any DDR defects due to reduced RNF168 levels. Consistent with a previous study 14 , we found that loss of Lkb1 dramatically affected the DDR and led to genome instability ( Supplementary  Fig. 4e-h) , which could be rescued by re-expression of LKB1-WT but not by a kinase-dead LKB1-KM mutant ( Supplementary  Fig. 4i,j) . To further dissect whether the DDR defects observed in LKB1-depleted cells are due to RNF168 malfunction triggered by activation of the mTORC1-S6K pathway, we expressed RNF168-SA and RNF168-SE mutants in Lkb1 -/-MEF cells. Upon treatment with IR or etoposide, we found that the expression of RNF168-SA (but not RNF168-SE) rescued DDR defects caused by Lkb1 loss (Fig. 6d-h and Supplementary Fig. 4k ).
To further investigate the pathological association of LKB1 loss with RNF168 expression and the DDR, we examined mouse tumour cells isolated from Kras G12D /Trp53 -/and Kras G12D /Lkb1 -/non-small-cell lung cancer (NSCLC) mouse models [31] [32] [33] . Compared with Kras G12D /Trp53 -/cells, Kras G12D /Lkb1 -/cells expressed significantly reduced levels of RNF168, and were much more sensitive to IR in the colongenic survival and comet assays, which were also well correlated with an impaired DDR, as indicated by γ H2A.X and 53BP1 foci imaging experiments ( Supplementary Fig. 5a-g) .
Expression of RNF168-SA suppresses tumorigenesis initiated by LKB1 loss.
As LKB1 deficiency triggered by mTORC1 activation has been linked to cancer initiation and progression, inhibition of RNF168 by mTORC1-S6K may have a substantial role in leading to genome instability and eventually tumorigenesis in LKB1-null background. Consistently, the expression of RNF168-SA, but not RNF168-SE, significantly increased 53BP1 foci formation and suppressed xenograft tumour growth in -LKB1 null A549 tumour cells without affecting cell proliferative features ( Supplementary Fig. 6a-e ). To further investigate the potential role of RNF168-S60 phosphorylation in tumorigenesis within the Lkb1-loss background, we chose a well-established spontaneous NSCLC mouse model (Kras G12D /Lkb1 L/L ) 33 , in which tumours are initiated by CRE excision-induced Kras-G12D expression and Lkb1 depletion. As indicated (Fig. 7a ), via nasal inhalation method, the mice were treated with a lentivirus expressing both CRE recombinase and RNF168-SA or RNF168-SE mutant simultaneously. We found that co-expression of RNF168-SA, but not RNF168-SE, dramatically suppressed the tumour number and the total tumour burden in all 6 mice tested 10 weeks post-treatment ( Fig. 7b-d and Supplementary Fig. 6f ). Notably, dramatically weaker γ H2A.X staining was detected in RNF168-SA-treated lung tissues (both tumour and non-tumour tissues), indicating that RNF168-SA may inhibit tumorigenesis via promoting the DDR (Fig. 7e-g) . To examine whether depletion of RNF168 in the Lkb1-WT background would be sufficient to promote tumorigenesis in combination with Kras G12D , we performed another similar experiment by treating Kras G12D mice with a lentivirus expressing CRE and a Cas9-small guide RNA (sgRNA) system targeting RNF168 ( Supplementary Fig. 6g ). However, depletion of RNF168 did not significantly increase tumour number or tumour burden ( Supplementary Fig. 6h-j) . Taken together, the results outlined above suggest that inhibition of RNF168 by the mTORC1-S6K pathway may be required for tumorigenesis driven by Lkb1 loss, although loss of RNF168 itself is not sufficient to initiate tumorigenesis in WT LKB1/ mTORC1-S6K background.
Discussion
mTOR, the central modulator of cellular homeostasis, has been implicated in genome integrity maintenance, and accumulated evidence has suggested that mTOR inhibition by nutrients and caloric restriction contributes to cancer prevention and extended lifespan 11, 12, 19 . Consistently, there are reports suggesting that the Supplementary Fig. 8 . mTORC1 pathway interplays between the DDR and the repair system 18, 20, 34 , although the detailed molecular mechanisms are largely unknown. In this study, we characterized a dual-module regulation of RNF168 by the mTORC1-S6K pathway. Ser60 phosphorylation not only inhibits RNF168 intrinsic E3 ligase activity but also promotes its proteolysis by TRIP12. As RNF168 is responsible for building up polyubiquitin chains to facilitate loading of non-homologous end joining and homologous recombination repair complexes at the damage sites, inhibition of RNF168 function would prevent timely repair of DSBs, which may accumulate and subsequently trigger severe genomic defects that can lead to permanent growth arrest or malignant transformation of cells. Thus, our finding established a molecular link between growth signals and genome stability via phosphorylation of RNF168 by mTORC1-S6K. Interestingly, we observed that RNF168 levels were dramatically accumulated within 30 min after amino acid deprivation, and decreased even faster (in 10 min) after amino acid re-feeding ( Fig. 4j) , indicating that the RNF168 levels are very sensitive to the activation of the mTORC1-S6K pathway and that they may fluctuate with the amount of nutrients in the extracellular environment. Thus, inhibition of RNF168 by the mTORC1-S6K pathway may also contribute to genome instability and eventually lead to physiological defects of the Supplementary Table 3 . Unprocessed original scans of blots are in Supplementary Fig. 8 . Supplementary Table 3 .
organism after long-term uptake of excessive nutrients, in addition to increased production of reactive oxygen species by active mTORC1 signalling [35] [36] [37] [38] [39] . LKB1 is a tumour suppressor that is frequently mutated in various cancers, including lung cancer 40 . mTORC1 signalling is aberrantly activated after loss of LKB1 through multiple characterized mechanisms [41] [42] [43] and is considered the major mechanism of how LKB1 loss contributes to oncogenesis. In this study, we identified an association between the LKB1 genetic status and RNF168 protein abundance. Notably, depletion of LKB1 sharply reduces RNF168 levels, whereas inhibition of the mTORC1-S6K pathway efficiently restored RNF168 expression ( Fig. 6c ), suggesting that the regulation of RNF168 by LKB1 is largely through the mTORC1-S6K pathway. In keeping with low RNF168 expression, Lkb1-null MEF cells and Kras G12D /Lkb1 -/mouse tumour cells were defective in the DDR and more sensitive to IR (Fig. 6e-h and Supplementary Figs. 4e-j and 5b-g). Expression of RNF168-SA, which is resistant to mTORC1-S6Kmediated inhibition, drastically restored DDR defects in Lkb1-null MEF cells ( Fig. 6e-h ) and suppressed spontaneous tumorigenesis in the Kras G12D /Lkb1 L/L NSCLC mouse model ( Fig. 7a-g) , supporting a crucial role of RNF168 inhibition in tumorigenesis initiated by LKB1 loss. It is noteworthy to mention that as we treated mice with a lentiviral vector expressing RNF168-SA mutant via nasal inhalation method, the amount of RNF168-SA protein expressed in mouse lung could not be precisely controlled to physiological levels. Better genetic models may be required to fully evaluate the actual tumoursuppressing function of RNF168-SA in LKB1-null cancers.
Taken together, our study reveals the mTORC1-S6K-RNF168 signalling axis, by which extracellular growth signals or intrinsic Lkb1 loss interplays with the DDR system ( Fig. 7h ). Our results also indicate that mTORC1 signalling not only has an essential role in supporting tumour cell growth and survival but also participates in the onset stage of cancer by promoting genome instability. In addition to Ser60 phosphorylation-mediated RNF168 inhibition, additional signalling pathways may also modulate RNF168 function or stability. It would also be interesting to dissect whether certain protein phosphatases specifically protect RNF168 from mTORC1mediated inhibition through dephosphorylating RNF168-Ser60. Certainly, more research efforts are warranted to fully understand the link between extracellular signals and DNA damage repair systems, and how genome integrity is affected in physiological and pathological conditions.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-017-0033-8. was mixed with 1 μ M RNF168 proteins (BSA and distilled H 2 O as a control) in 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM MgCl 2 , 1 μ M ZnCl 2 and 1 mM TCEP. The reactions were incubated at 37 °C for 30 min and stopped by nonreduced SDS-PAGE loading buffer, and analysed by GelCode Blue Stain reagent.
Neutral comet assays. Single-cell gel electrophoretic comet assays were performed under neutral conditions following standard procedures 51, 52 . Cells were seeded the day before IR treatment and recovered in the indicated culture condition for 30 min or 3 h after IR (50 Gy Class-switch recombination assays. Class-switch recombination assays were performed as described previously 53 . Briefly, WT and RNF168-SA/SE KI mice were killed at 5-6 weeks of age, and the EasySep Mouse B Cell Isolation Kit (STEMCELL) was used to purify primary B cells from the spleen. B cells (2 × 10 6 ) were stimulated with lipopolysaccharide (LPS; 20 μ g ml -1 ; Sigma) plus recombinant mouse IL-4 (25 ng ml -1 ; Novoprotein) for the indicated time, and the population of IgG1-expressing cells was examined by FACS analysis with an anti-IgG1 antibody (1:200; BD Bioscience) and an anti-B220 antibody (1:200; eBioscience).
Haematoxylin and eosin staining and immunohistochemistry. Mice lung tissues were inflated with 1 ml 4% paraformaldehyde, fixed overnight and dehydrated in ethanol, embedded in paraffin, sectioned (5 μ m) and stained with haematoxylin and eosin (H&E, Sigma). H&E stained lung lobes were placed on a scanning machine (Perkin Elmer Vectra 2, one mouse at a time). Scanned areas were selected manually and scanned automatically by the machine, and a final image compiling the scans was automatically generated by the system for each mouse. For immunohistochemistry staining, slides were deparaffinized in xylene and ethanol, and rehydrated in water. Slides were quenched in hydrogen peroxide (3%) to block endogenous peroxidase activity. Antigen retrieval was performed by heating slides in a microwave for 20 min in sodium citrate buffer (pH 6.0).
The primary antibodies were incubated at 4 °C overnight and then the SPlink Detection Kit (Biotin-Streptavidin HRP Detection Systems) was used according to the manufacturer's instructions. To calculate the percentages of cells that were positive for γ H2A.X in immunohistochemistry, in total, > 100 high power fields were randomly selected for statistical analysis.
Intestinal villi regeneration assay. 8-week-old WT and RNF168-SA/SE KI mice (6 mice per group) were treated with 10 Gy whole-body irradiation and housed in a specific pathogen-free environment in the Shanghai Institute of Biochemistry and Cell Biology. Mice were killed 5 days after whole-body irradiation, and the small intestines were used for histological analyses. The length of the regenerating villi were quantified (20 fields per genotype using × 20 magnification) after H&E staining of paraffin sections.
A549 xenograft tumorigenesis assay. 2 × 10 6 A549 cells in 100 μ l PBS were injected into the dorsal flank of 6-week-old randomly grouped (6 mice per group) male BALB/c nude mice. Tumour growth was monitored regularly for up to 50 days by measuring the diameter of tumours with digital calipers. Tumour volume was calculated by the formula: volume = (width) 2 × length/2.
Statistics and reproducibility.
The significance of experimental data was determined by two-tailed Student's unpaired t-test, except significance between RNF168 and pS6 levels in clinical samples, which was by Chi-squared test. P < 0.05 was considered significant. Individual in vitro experiments were performed three times unless otherwise indicated. For experiments with animal models, the experiments were independently repeated two times with similar results. Numbers are indicated in the figure legends. Results are expressed as mean ± s.e.m. (NS, not significant; *0.01 < P < 0.05, **0.001 < P < 0.01 and ***P < 0.001). No adjustments were made for multiple comparisons. In vitro experiments were not randomized and the investigators were not blinded to group allocation. In vivo experiments were randomized, but the investigators were not blinded to group allocation. Animals were excluded from experiments if they died before the end of experiments and were performed with adequate numbers to ensure statistical evaluation. The data from all experiments were normally distributed, and the variance between groups that were statistically compared was similar. No statistical method was used to predetermine sample size. Sample size was chosen on the basis of literature in the field.
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Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded to group allocation during data collection and/ or analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
